Abstract
HPV vaccines in Brazil and the world
Highlights
Human papillomavirus (HPV), the most common newly acquired, sexually transmitted infection worldwide, infects about 75% of sexually active individuals in their lifetimes
Two vaccines have been developed, a quadrivalent vaccine that protects against HPV 16, 18, 6 and 11 (Merck & Co., USA) and a bivalent vaccine that protects against HPV 16 and 18 (Glaxo Smith-Kline, Belgium)
Both vaccines are composed of HPV L1 proteins that have spontaneously self-assembled into virus-like particles (VLPs)
Summary
Human papillomavirus (HPV), the most common newly acquired, sexually transmitted infection worldwide, infects about 75% of sexually active individuals in their lifetimes. In a number of clinical trials conducted in thousands of subjects in many countries since 1998, the safety, immunogenicity and efficacy of these HPV VLP vaccines have been demonstrated [3]. Prophylactic efficacy was measured considering HPV infection and disease endpoints, high-grade cervical intraepithelial neoplasia or worse for the bivalent and quadrivalent vaccines, as well as vulvar
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call